Payment overview · 2025
General Payments
$3,437.45
133 reported records · 6 companies
Healthcare provider profile · identity verified
Sajjad Mohammad, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1033290242
Verified facts
What the public records show
CMS Open Payments records show Sajjad Mohammad, M.D received $3,437.45 in general payments during 2025 across 133 reported records.
ViiV Healthcare Company accounted for 77.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Dovato, Ozempic, Verquvo.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 550 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Descovy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $2,660.43 | 77.4% | 99 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $534.36 | 15.6% | 26 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.86 | 3.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.49 | 2.2% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.53 | 1.2% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $21.78 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,843.64 | 130 |
| Travel and Lodging | $593.81 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $880.21 | 39 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $449.31 | 32 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $404.94 | 15 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $152.76 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.86 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $77.49 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $41.36 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 550 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
550 | 67 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
126 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1094 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 567 | 70 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 550 | 67 |
| Metformin Hcl | Metformin Hcl | 380 | 43 |
| Gabapentin | Gabapentin | 373 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 362 | 57 |
| Lisinopril | Lisinopril | 361 | 47 |
| Omeprazole | Omeprazole | 355 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 323 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 317 | 46 |
| Trazodone Hcl | Trazodone Hcl | 255 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 36 |
| Nifedipine Er | Nifedipine | 249 | 30 |
| Mirtazapine | Mirtazapine | 242 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 37 |
| Furosemide | Furosemide | 215 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 197 | 31 |
| Simvastatin | Simvastatin | 190 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 187 | 21 |
| Losartan Potassium | Losartan Potassium | 181 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 46 |
| Famotidine | Famotidine | 167 | 22 |
| Levetiracetam | Levetiracetam | 166 | 13 |
| Buspirone Hcl | Buspirone Hcl | 158 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 155 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 144 | 34 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 135 | 14 |
| Eliquis | Apixaban | 134 | 32 |
| Ammonium Lactate | Ammonium Lactate | 133 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 11 |
| Dovato | Dolutegravir Sodium/Lamivudine | 126 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 117 | 15 |
| Latanoprost | Latanoprost | 117 | 17 |
| Finasteride | Finasteride | 116 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 113 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 24 |
| Carvedilol | Carvedilol | 107 | 19 |
| Jardiance | Empagliflozin | 105 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 103 | 14 |
| Montelukast Sodium | Montelukast Sodium | 102 | 20 |
| Januvia | Sitagliptin Phosphate | 101 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | suppressed |
| Entresto | Sacubitril/Valsartan | 96 | 18 |
| Prezcobix | Darunavir/Cobicistat | 95 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 92 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 89 | 11 |
| Azithromycin | Azithromycin | 88 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 14 |
| Divalproex Sodium | Divalproex Sodium | 85 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 85 | 17 |
| Meloxicam | Meloxicam | 84 | 25 |
| Trulicity | Dulaglutide | 84 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 69 | 11 |
| Lorazepam | Lorazepam | 68 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 14 |
| Farxiga | Dapagliflozin Propanediol | 64 | suppressed |
| Naproxen | Naproxen | 64 | 15 |
| Ozempic | Semaglutide | 64 | 12 |
| Valacyclovir | Valacyclovir Hcl | 63 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 20 |
| Vascepa | Icosapent Ethyl | 61 | suppressed |
| Lactulose | Lactulose | 60 | 19 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 59 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 59 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 58 | 11 |
| Clonidine Hcl | Clonidine Hcl | 57 | 13 |
| Ibuprofen | Ibuprofen | 56 | 17 |
| Enalapril Maleate | Enalapril Maleate | 54 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 53 | suppressed |
| Allopurinol | Allopurinol | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Sucralfate | Sucralfate | 45 | suppressed |
| Tivicay | Dolutegravir Sodium | 45 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 44 | 15 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 43 | 11 |
| Nystatin | Nystatin | 43 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Novolog Flexpen | Insulin Aspart | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 13 |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 38 | 37 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 36 | suppressed |
| Celecoxib | Celecoxib | 34 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 34 | suppressed |
| Nadolol | Nadolol | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Rexulti | Brexpiprazole | 32 | 13 |
| Linzess | Linaclotide | 31 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 30 | suppressed |
| Darunavir | Darunavir | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 16 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Hydroxyurea | Hydroxyurea | 28 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 17 |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Entecavir | Entecavir | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 18 |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Lamivudine | Lamivudine | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Lamivudine Hbv | Lamivudine | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 12 |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 17 | suppressed |
| Ritonavir | Ritonavir | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 15 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Abacavir | Abacavir Sulfate | 13 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Etravirine | Etravirine | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 12 | suppressed |
| Ultra Comfort | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Levemir Flextouch | Insulin Detemir | 11 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,437.45 · 133 records | ViiV Healthcare Company | APRETUDE, Biktarvy, CABENUVA, DOVATO, NUZYRA, Ozempic, RUKOBIA, SUBLOCADE, VERQUVO | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error